Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) 是一种具有潜在抗肿瘤活性的原癌基因 c-Met (HGFR) 的口服生物可利用抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 178 | 现货 | ||
5 mg | ¥ 460 | 现货 | ||
10 mg | ¥ 646 | 现货 | ||
25 mg | ¥ 1,143 | 现货 | ||
50 mg | ¥ 1,896 | 现货 | ||
100 mg | ¥ 2,950 | 现货 | ||
500 mg | ¥ 5,990 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 521 | 现货 |
产品描述 | Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity. |
体外活性 | Capmatinib was found to be highly selective for MET over other kinases.?It was active against cancer models that are characterized by MET amplification, marked MET overexpression, MET exon 14 skipping mutations, or MET activation via expression of the ligand hepatocyte growth factor (HGF)[1]. |
体内活性 | In cancer models where MET is the dominant oncogenic driver, anticancer activity could be further enhanced by combination treatments, for example, by the addition of apoptosis-inducing BH3 mimetics.?The combinations of capmatinib and other kinase inhibitors resulted in enhanced anticancer activity against models where MET activation co-occurred with other oncogenic drivers, for example EGFR activating mutations[1]. |
别名 | INCB28060 2HCl.H2O, INC-280 2HCl.H2O, NVP-INC280 2HCl.H2O |
分子量 | 503.36 |
分子式 | C23H21Cl2FN6O2 |
CAS No. | 1865733-40-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (59.6 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9866 mL | 9.9332 mL | 19.8665 mL | 49.6662 mL |
5 mM | 0.3973 mL | 1.9866 mL | 3.9733 mL | 9.9332 mL | |
10 mM | 0.1987 mL | 0.9933 mL | 1.9866 mL | 4.9666 mL | |
20 mM | 0.0993 mL | 0.4967 mL | 0.9933 mL | 2.4833 mL | |
50 mM | 0.0397 mL | 0.1987 mL | 0.3973 mL | 0.9933 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Capmatinib 2HCl.H2O 1865733-40-9 Tyrosine Kinase/Adaptors c-Met/HGFR S114 SNU-5 ATP competitive Balb/c nu/nu mice U-87MG INCB-28060 dihydrochloride INCB28060 2HCl.H2O orally active Capmatinib dihydrochloride Capmatinib 2HCl.H-2O INC-280 2HCl.H2O INC280 dihydrochloride Apoptosis NVP-INC280 2HCl.H2O inhibit Inhibitor H441 inhibitor